Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.
JOURNAL CLUB RESPIRATORY MEDICINE
Inflammatory Polyps of the Nasal Turbinates of Cats: An Argument for Designation as Feline Mesenchymal Nasal Hamartoma Greci V, Mortellaro CM, Olivero D, et al. Journal of Feline Medicine and Surgery
The term inflammatory polyps of the nasal turbinates (IPNT) has been used to describe a rare, benign disease of
the upper respiratory tract (URT) of cats. Clinical signs of this disease include sneezing, stertor, epistaxis and, less commonly, serous nasal discharge or facial deformation. These cystic, often red-grey colored polyps originate in the nasal passages and can expand into the nasopharynx. Inflammatory nasal polyps are in contrast to the more solid, white-pink colored nasopharyngeal polyps (NPPs) that originate in the eustachian tube of cats, potentially extending into the middle ear and/or nasopharynx. While cats with both IPNT and NPP tend to be young at time of presentation (< 1 year), the diseases can often be differentiated clinically since NPPs are not associated with epistaxis. *O UIJT TUVEZ UIF BVUIPST DPNQBSFE UIF DMJOJDBM BOE IJTUPQBUIPMPHJD GJOEJOHT PG DBUT XJUI *1/5 UP QVCMJTIFE EFTDSJQUJPOT
of nasal hamartomas (NHs) in children. The mean age of the cats was 10.8 months (range, 6–18 months), with a mean duration PG DMJOJDBM TJHOT PG NPOUIT SBOHF
m NPOUIT /POF PG UIF
cats had a history of URT infection as kittens. Histopathology (described at length in the manuscript) was
consistent with that of human mesenchymal NH, in that the tissues were composed of 2 or more mesenchymal compo- nents and fibrous tissue, with appropriate immunohistochemi- cal staining properties. The authors suggest that this may be a hereditary or congenital disease; however, the etiology is unknown. Despite the locally invasive nature of these lesions and radiographic changes consistent with malignancy, NHs carry a good prognosis with the potential for cure with com- plete excision. The authors conclude by proposing that IPNT be renamed feline mesenchymal nasal hamartoma to more accurately describe the condition.
CRITICAL POINTS
r *OGMBNNBUPSZ QPMZQT PG UIF OBTBM UVSCJOBUFT (IPNT) describes a rare, benign disease of the URT of cats (usually young cats).
r 5IJT TUVEZ DPNQBSFE UIF DMJOJDBM BOE IJTUPQBUIPMPHJD GJOEJOHT PG DBUT XJUI *1/5 UP published descriptions of nasal hamartomas (NHs) in children.
r )JTUPQBUIPMPHZ XBT DPOTJTUFOU XJUI UIBU PG human mesenchymal NH.
r 5IF BVUIPST QSPQPTFE SFQMBDJOH UIF UFSN IPNT with feline mesenchymal nasal hamartoma to more accurately describe the disease.
Claire R. Sharp, BSc, BVMS(Hons), MS, Diplomate ACVECC, Tufts University DERMATOLOGY
Masitinib Decreases Signs of Canine Atopic Dermatitis: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Cadot P, Hensel P, Bensignor E, et al. Veterinary Dermatology
Masitinib is a selective tyrosine kinase inhibitor that downregulates mast cell functions. This study investigated the efficacy and safety of masitinib (Kinavet CA-1, kinavet.com) for the treatment of canine atopic dermatitis (AD). Dogs with "% SFDFJWFE NBTJUJOJC PSBMMZ BU NH LH 2 ) n = 202) or control (n
GPS PG NBTJUJOJC USFBUFE EPHT WFSTVT *O UPUBM PG DPOUSPM EPHT 1
DPSUJDPTUFSPJET DPOUSPM HSPVQ 1 HSPVQ 1
PG UIF TUVEZ QPQVMBUJPO $"%&4* BEWFSTF FGGFDUT NBTJUJOJC USFBUFE WFSTVT SFTQPOTF SBUFT XFSF
Masitinib showed a greater risk for reversible protein loss from the kidneys, mostly during the first 3 months of treatment; surveillance of serum albumin and proteinuria every other week was recommended. Masitinib was shown to be an effective and mostly well-tolerated treatment for canine AD, including severe and refractory cases.
Sandra Koch, DVM, MS, Diplomate ACVD, University of Minnesota 76 Today's Veterinary Practice January/February 2012
JO "% QFS UIF $BOJOF "UPQJD %FSNBUJUJT &YUFOU; BOE 4FWFSJUZ *OEFY $"%&4* XJUI B TDPSF PG ö BU XFFL JO
5IF NFBO SFEVDUJPO JO QSVSJUVT TDPSF PG TFWFSFMZ QSVSJUJD EPHT XBT EPHT QSFTFOUFE XJUI TFWFSF DPOUSPM
CRITICAL POINTS
r 0SBM NBTJUJOJC NBZ CF BO BMUFSOBUJWF USFBUNFOU for canine AD, particularly in severe and refractory cases.
r 3FWFSTJCMF QSPUFJO MPTT GSPN UIF LJEOFZ JT B reported adverse effect, mostly during the first 3 months of therapy; therefore, regular monitor- ing of albumin and proteinuria is recommended.
XFFLT 5IFSF XBT B SFEVDUJPO
'PS EPHT SFTJTUBOU UP DZDMPTQPSJO BOE PS NBTJUJOJC HSPVQ WFSTVT WFSTVT
DPOUSPM